ASP Isotopes (NASDAQ:ASPI) Sets New 1-Year High – Time to Buy?

ASP Isotopes Inc. (NASDAQ:ASPI) hit a new 52-week high during trading on Saturday . The company traded as high as $10.69 and last traded at $10.49, with a volume of 11928955 shares traded. The stock had previously closed at $9.65.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group boosted their price target on ASP Isotopes from $8.50 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st.

ASP Isotopes Price Performance

The company’s 50-day moving average is $7.77 and its 200-day moving average is $6.05. The firm has a market cap of $879.90 million, a price-to-earnings ratio of -17.20 and a beta of 3.35. The company has a current ratio of 7.21, a quick ratio of 7.17 and a debt-to-equity ratio of 0.80.

Institutional Investors Weigh In On ASP Isotopes

Large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its holdings in shares of ASP Isotopes by 31.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 158,226 shares of the company’s stock worth $717,000 after buying an additional 37,948 shares in the last quarter. Avantax Advisory Services Inc. bought a new position in ASP Isotopes in the fourth quarter valued at about $45,000. Intech Investment Management LLC acquired a new position in ASP Isotopes during the fourth quarter worth about $129,000. Virtu Financial LLC raised its stake in ASP Isotopes by 403.0% during the fourth quarter. Virtu Financial LLC now owns 58,812 shares of the company’s stock worth $266,000 after acquiring an additional 47,119 shares in the last quarter. Finally, LPL Financial LLC bought a new position in shares of ASP Isotopes in the fourth quarter worth about $54,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.